Immunodiagnostic Systems, the Newcastle based specialist in-vitro diagnostics company, announced good sales and profitability growth vs. H1 2009 in its interim results to September 30th 2010. Sales were up 34% to £22.6 million - driven by growth in Vitamin D sales (in both manual and automated IDS-iSYS products). Pre-tax profits were up 44% to £6.6 million.

The IDS-iSYS launch continued to go well, with 66 instruments being placed during the period (vs. 47 in the preceding half). At the end of H1 FY2010/11, a total of 140 instruments had been placed, with a further 30 by the end of November 2010. The average per instrument revenue of UK based iSYS systems has risen to £96,000 per annum (H1 2009/10 £86,000), though European based systems fell slightly to €74,000 (H1 2009/10 €76,000). Overall IDS-iSYS revenue has increased to £3.3 million.

The company reported that H2 trading is in line with management expectations.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here